Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.46 |
| ▸ | TRPV3 | Q8NET8 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PDE2A | O00408 | 2/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.38 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.35 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL469196 | 1.00 | TRPV4 (0.46) | TRPV4TRPV3ALDH1A1PDE2AP2RX7 | |
| SCHEMBL14612275 | 1.00 | TRPV4 (0.46) | TRPV4TRPV3ALDH1A1PDE2AP2RX7 | |
| SCHEMBL19831923 | 0.86 | TRPV4 (0.43) | TRPV4TRPV3PDE2AP2RX7GPR139 | |
| SCHEMBL15354698 | 0.84 | TRPV4 (0.44) | TRPV4TRPV3P2RX7GPR139 | |
| SCHEMBL20180478 | 0.84 | TRPV4 (0.44) | TRPV4TRPV3P2RX7GPR139 | |
| SCHEMBL31477305 | 0.84 | TRPV4 (0.44) | TRPV4TRPV3PDE2AP2RX7GPR139 | |
| SCHEMBL16449367 | 0.84 | TRPV4 (0.44) | TRPV4TRPV3P2RX7GPR139 | |
| SCHEMBL14313737 | 0.84 | TRPV4 (0.47) | TRPV4TRPV3PDE2AP2RX7 | |
| SCHEMBL24974247 | 0.83 | TRPV4 (0.43) | TRPV4TRPV3PDE2AP2RX7GPR139 | |
| SCHEMBL24973993 | 0.83 | TRPV4 (0.43) | TRPV4TRPV3PDE2AP2RX7GPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10179782-B2 | Substituted sulfonamide compounds | GENENTECH, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| EP-2410857-B1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME (US) | 2014-01-29 | — | — | EP | disclosed |
| US-20120021074-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | MERCK SHARP & DOHME CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-7173031-B2 | Pyrrolotriazine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179782-B2 | Substituted sulfonamide compounds | TRPA1, TRPV1, TRPV5 | TRPV4 7/4885TRPV3 5/4885ALDH1A1 461/4885 |
| US-20120021074-A1 | P2X3, RECEPTOR ANTAGONISTS FOR TREATMENT OF PAIN | P2RX3, P2RX1, P2RX2 | TRPV4 27/4885TRPV3 19/4885ALDH1A1 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.